ELYM ELIEM THERAPEUTICS INC

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.

Guggenheim Securities Healthcare Innovation Conference

Format: Fireside chat and one-on-one investor meetings

Date: November 11-12, 2024

Stifel 2024 Healthcare Conference

Format: Fireside chat and one-on-one investor meetings

Date: November 18-19, 2024

36th Annual Piper Sandler Healthcare Conference

Format: Fireside chat and one-on-one investor meetings

Date: December 3-5, 2024

7th Annual Evercore ISI HealthCONx Conference

Format: Fireside chat and one-on-one investor meetings

Date: December 3-5, 2024

The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Climb Bio, Inc.

Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit .

Investors

Chris Brinzey

ICR Healthcare



339-970-2843

Media

Jon Yu

ICR Healthcare



475-395-5375



EN
31/10/2024

Underlying

ELYMELIEM THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio to be Added to the Nasdaq Biotechnology Index WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio’s inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are class...

December 19, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Third Quarter 2024 Financial Results and Business Hi...

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls Highlights Timing of Key Upcoming Milestones Cash Runway Remains through 2027 Expected to Enable Delivery of Key Value Inflection Points WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Clim...

November 12, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has he...

November 11, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Present at Upcoming Investor Conferences WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below. Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 11-12, 2024 Stifel 2024 Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 18-19, 2024 36th Annual Piper Sandler Healthcare ConferenceFormat: Fireside ch...

October 31, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Provide Budoprutug Development Strategy and Corporate Upd...

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trials in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 1...

October 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch